Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
139K
-
Shares change
-
+36.8K
-
Total reported value, excl. options
-
$6.41M
-
Value change
-
+$1.7M
-
Number of buys
-
2
-
Number of sells
-
-1
-
Price
-
$46.06
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q4 2023
3 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q4 2023.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 139K shares
of 77.3M outstanding shares and own 0.18% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (5.67M shares), FMR LLC (5.66M shares), DRIEHAUS CAPITAL MANAGEMENT LLC (4.35M shares), WELLINGTON MANAGEMENT GROUP LLP (4.16M shares), Polar Capital Holdings Plc (3.07M shares), Capital World Investors (2.68M shares), Capital International Investors (2.46M shares), COMMODORE CAPITAL LP (2.17M shares), Paradigm Biocapital Advisors LP (2.13M shares), and BlackRock Inc. (2.07M shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.